empower semaglutide reddit Safety risks in the GLP-1 market: an update on weight loss medication, May 2026 – Partnership for Safe Medicines A GLP-1 weight loss boom
Description
Glucagon like peptide 1 receptor agonists in the treatment of obesity
One of the most overlooked facts is that many patients are not stopping because they gave up. They are stopping because coverage changed, formularies shifted, prior authorizations were denied, side effects were unmanaged, or costs became impossible
All needles should be treated as if they carry disease
Specifically, in the 12 mg group, 26% of participants lost 30% or more of their body weight
Hannon J, Hoyer D
